

Mat '214, 1951, 873, 132, 003

Spivack


10/016146

Page

57


ACCESSION NUMBER: 2000:456866 CAPLUS
DOCUMENT NUMBER: 133:84239
TITLE: Method of using an integrin antagonist and one or more antineoplastic agents as a **combination** therapy in the treatment of neoplasia
INVENTOR(S): McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime L.
PATENT ASSIGNEE(S): G. D. Searle & Co., USA
SOURCE: PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038665	A2	20000706	WO 1999-US30670	19991222
WO 2000038665	A3	20001116		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2356462	AA	20000706	CA 1999-2356462	19991222
EP 1140193	A2	20011010	EP 1999-968529	19991222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002533387	T2	20021008	JP 2000-590619	19991222
PRIORITY APPLN. INFO.: US 1998-113786P P 19981223, no 102 date				
WO 1999-US30670 W 19991222				
AB	The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of an integrin antagonist and an antineoplastic agent.			
IT	50-18-0, Cyclophosphamide 51-21-8, 5-Fluorouracil 15663-27-1, Cisplatin 23214-92-8, Doxorubicin 33069-62-4, Paclitaxel 280105-13-7 280105-14-8 280105-17-1 280105-18-2 280105-19-3			
RL:	BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (integrin antagonist-antineoplastic agent combination for neoplasia treatment)			
RN	50-18-0 CAPLUS			
CN	2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9CI) (CA INDEX NAME)			




51-21-8 CAPLUS

2,4(1H,3H)-Pyrimidinedione, 5-fluoro- (9CI) (CA INDEX NAME)



RN 15663-27-1 CAPLUS


CN Platinum, diamminedichloro-, (SP-4-2)- (9CI) (CA INDEX NAME)



RN 23214-92-8 CAPLUS

CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 33069-62-4 CAPLUS

CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Spivack


10/016146



RN 280105-13-7 CAPLUS

CN .beta.-Alanine, N-[3-amino-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280105-14-8 CAPLUS

CN .beta.-Alanine, N-[3-[(hydroxyamino)carbonyl]-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 280105-17-1 CAPLUS

CN .beta.-Alanine, N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-, (3R)- (9CI) (CA INDEX NAME)


pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-,
(3R)- (9CI) (CA INDEX NAME)

bsolute stereochemistry.



RN 280105-18-2 CAPLUS
CN .beta.-Alanine, N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-
pyrimidinyl)amino]benzoyl]glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-, (3R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280105-19-3 CAPLUS
CN .beta.-Alanine, N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-
pyrimidinyl)amino]benzoyl]glycyl-3-(5-bromo-3-chloro-2-hydroxyphenyl)-,
(3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

